Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
2 clinical trials · Condition
◉ Watch Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
| Record | Firm | Date |
|---|---|---|
| Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma (NCT05202782) | Northwestern University | 2022-03-21 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275) | National Cancer Institute (NCI) | 2021-05-20 |
Track Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type automatically
Every clearance here is in the API, with alerts when new ones post.